

**Quality Committee - Chair's Highlight Report to Trust Board**

<b>Subject:</b>	Quality Committee Meeting	<b>Date:</b> 14 <sup>th</sup> November 2022
<b>Prepared By:</b>	Barbara Brady, Non -Executive Director	
<b>Approved By:</b>	Barbara Brady, Non -Executive Director	
<b>Presented By:</b>	Barbara Brady, Non -Executive Director	
<b>Purpose</b>		
	<b>Assurance</b>	

<b>Matters of Concern or Key Risks to Escalate</b>	<b>Major Actions Commissioned / Work Underway</b>
<ul style="list-style-type: none"> <li>▪ Capacity of Pharmacy team – implications for ‘On call’ arrangements and medicines reconciliation</li> <li>▪ Progress on CQC ‘Must Dos’</li> </ul>	<ul style="list-style-type: none"> <li>▪ Ongoing work on HSMR</li> <li>▪ Estates Quality Dashboard, with particular emphasis on water quality</li> </ul>
<b>Positive Assurances to Provide</b>	<b>Decisions Made</b>
<ul style="list-style-type: none"> <li>▪ Review of Never Events</li> <li>▪ Learning from Serious Incidents</li> <li>▪ Quality Impact of Industrial Action</li> <li>▪ Deep Dive into 3<sup>rd</sup> and 4<sup>th</sup> degree tears (maternity) concluded with no themes identified</li> </ul>	<ul style="list-style-type: none"> <li>▪ Approved revised workplan</li> <li>▪ Dr Aly Rashid agreed as Vice Chair</li> <li>▪ BAF, PR1 and PR2 to risk rating to remain unchanged. Discussed regarding tolerable risks and agree these remain unchanged</li> </ul>
<b>Comments on Effectiveness of the Meeting</b>	
<ul style="list-style-type: none"> <li>▪ Good discussion and debate on wide ranging issues related to Clinical Quality, enabled by good quality papers</li> </ul>	